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Abstract 
Objective 
To evaluate the feasibility, safety and efficacy of day-and-night hybrid closed-loop 
insulin delivery in adolescents with type 1 diabetes under free-living conditions. 
Research Design and Methods 
In an open-label randomized crossover study,12 suboptimally controlled adolescents 
on insulin pump therapy (age 14.6±3.1years; HbA1c 69±8mmol/mol [8.5±0.7%]; 
duration of diabetes 7.8±3.5years; mean±SD) underwent two 21-day periods 
comparing hybrid closed-loop insulin delivery and sensor-augmented insulin pump 
therapy in random order. During closed-loop, a model predictive algorithm 
automatically directed insulin delivery between meals and overnight; prandial 
boluses were administered by participants using a bolus calculator. 
Results 
The proportion of time that sensor glucose was in the target range (3.9 to 10mmol/l; 
primary endpoint) was increased during closed-loop intervention compared to 
sensor-augmented insulin pump therapy by 18.8±9.8 percentage points (mean±SD; 
p<0.001), the mean sensor glucose level was reduced by 1.8±1.3 mmol/l (p=0.001), 
and the time spent above target was reduced by 19.3±11.3 percentage points 
(p<0.001). The time spent with sensor glucose levels below 3.9mmol/l was low and 
comparable between interventions [difference 0.4 (-2.2 to 1.3) percentage points; 
median (IQR), p=0.33). Improved glucose control during closed-loop was associated 
with increased variability of basal insulin delivery (p<0.001) and an increase in total 
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daily insulin dose [53.5 (39.5 to 72.1) vs. 51.5 (37.6 to 64.3)U/day; p=0.006). 
Participants expressed positive attitudes and experience with closed-loop. 
Conclusions 
Free-living home use of day-and-night closed-loop in suboptimally controlled 
adolescents with type 1 diabetes is safe, feasible and improves glucose control 
without increasing the risk of hypoglycemia. Larger and longer studies are 
warranted.  
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The majority of adolescents and young adults with type 1 diabetes are poorly 
controlled (1-3) accelerating the onset of early micro- and macrovascular  
complications (4; 5).  Reduced therapy adherence linked to psychosocial and 
physiological changes in adolescence is contributory (6) as omissions of prandial 
insulin boluses are frequent (7), and acceptance of insulin pump therapy and 
continuous glucose monitoring systems is lower (8-10). Threshold-suspend and 
predictive low glucose management insulin pump therapy may alleviate the burden 
of hypoglycemia (11; 12) but do not address the issue of hyperglycemia, the major 
challenge of diabetes management in adolescence. 
The artificial pancreas (closed-loop systems) modulates insulin delivery below 
and above pre-set insulin pump delivery in response to real-time sensor glucose 
levels and can potentially reduce both hypo- and hyperglycemia. Following 
evaluations in children and adolescents in laboratory settings (13-15) and diabetes 
camps (16-18), first at-home studies of up to three-month applications of overnight 
closed-loop have demonstrated improved glucose control and reduced the burden of 
hypoglycemia (19-21). However, randomized outpatient trials evaluating day-and-
night closed-loop in adolescents are limited to a maximum of a one week follow up 
(16; 18; 22). 
Here, we present results of a 21-day-long day-and-night closed-loop trial in 
young people aged 10 to 18 years with suboptimally controlled type 1 diabetes 
during free living settings. We hypothesized that prolonged use of a 24/7 hybrid 
single hormone closed-loop system without remote monitoring or close supervision 
would be feasible, safe and improve glycemic control compared to sensor-
augmented insulin pump therapy.  
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Research Design and Methods 
Study management and regulatory approvals 
The study received approval from the local independent research ethics 
committee and the UK competent authority (Medicines & Health products Regulatory 
Agency). An independent Data Safety and Monitoring Board oversaw the study.  
Participants 
Study participants were identified from pediatric diabetes clinics at 
Addenbrooke’s Hospital (Cambridge, United Kingdom) and University College 
London Hospital (London, United Kingdom). Key inclusion criteria were age 10-18 
years, diagnosis of type 1 diabetes, treatment with insulin pump therapy for at least 
three months, willingness to perform at least four fingerstick glucose measurements 
per day, and HbA1c ≤11% (97mmol/mol). Exclusion criteria included established 
nephropathy, neuropathy, or proliferative retinopathy, total daily insulin dose ≥2.0 
U/kg or <10 U/day, significant hypoglycaemia unawareness, more than one incident 
of severe hypoglycemia within 6 months prior to enrollment, more than one episode 
of diabetic ketoacidosis within 12 months prior to enrolment, pregnancy and breast-
feeding. Participants aged ≥16 years and parents or guardians of participants aged 
<16 years signed informed consent; written assent was obtained from minors before 
study related activities.  
Study design and procedures 
The study adopted an open-label, randomized, two-period crossover design 
comparing automated closed-loop insulin delivery with sensor-augmented pump 
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therapy in free-living home settings (Supplemental Material Figure S1). Study 
intervention periods lasted three weeks each with a 1 to 4-week washout period.  
At enrolment, blood samples were taken for analysis of HbA1c. Random 
C-peptide levels were measured with concomitant plasma glucose >4mmol/l. At the 
start of the run-in phase, participants received training regarding the use of the study 
pump (DANA Diabecare R; Sooil, Seoul, South Korea) and the study real-time 
continuous glucose monitoring system (FreeStyle Navigator II; Abbott Diabetes 
Care, Alameda, CA) which are off-the-shelf devices and do not offer low glucose 
suspend functionality. Rapid-acting insulin analog aspart (Novo Nordisk, Bagsvaerd, 
Denmark) or lispro (Eli Lilly, Indianapolis, US) was administered by the pump. 
Participants used a standard bolus calculator for all meals throughout the study.   
At the end of the 1 to 2-week run-in period, compliance in the use of study 
pump and continuous glucose monitoring were assessed. Participants with at least 
5 days’ worth of continuous glucose monitoring data were randomly assigned to 
receive either 3 weeks of automated closed-loop insulin delivery followed by sensor-
augmented pump therapy, or vice versa. Permuted block randomization was applied 
and assignment was unblinded.  
The two intervention periods were separated by a 1 to 4-week washout period 
during which the participants could continue using the study insulin pump. 
Continuous glucose monitoring was discontinued during washout. 
On the first day of the closed-loop period, participants attended the clinical 
research facility. This 2 to 3-hour visit included training on initiation and 
discontinuation of the closed-loop system, switching between closed-loop and usual 
pump therapy, meal bolus procedure, and the use of study devices during exercise. 
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Competency on the use of closed-loop system was assessed. Following discharge, 
participants continued the study intervention for the next 21 days under free-living 
settings in their home and school environment. The participants were free to 
consume meals of their choice and no restrictions were imposed on travelling. We 
encouraged participants to continue closed-loop use during exercise, and to 
announce physical activity to the algorithm. However, participants were advised to 
discontinue closed-loop and follow their usual insulin pump therapy for activities such 
as diving or contact sports. At the end of the closed-loop intervention, participants 
completed a feedback questionnaire to assess user-friendliness and satisfaction with 
study devices. Participants were not remotely monitored or supervised.  
The number of planned contacts with the study team was identical during the 
two study periods. The study pump and the study real-time continuous glucose 
monitoring device were used during both study periods. Participants were advised to 
calibrate the continuous glucose monitoring device according to the manufacturer’s 
instructions; they were free to decide on alarm settings for the continuous glucose 
monitoring device. All participants were provided with a 24-hour telephone helpline to 
contact the study team in the event of study-related issues. All helpline contacts 
resulting in an immediate action by research staff (i.e. device replacement, adverse 
event reporting) were documented. 
Closed-loop system 
The FlorenceD2A closed-loop system (University of Cambridge, Cambridge, 
UK)(23) comprised a model predictive control algorithm (version 0.3.41, University of 
Cambridge) residing on a smartphone (Galaxy S4, Samsung, South Korea), which 
communicated wirelessly with continuous glucose monitoring receiver through a 
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purpose made translator unit (Triteq, Hungerford, UK) (Supplemental Material 
Figure S2). Every 12 min, the control algorithm calculated an insulin infusion rate 
which was set on the study insulin pump. In this trial, a hybrid closed-loop approach 
was applied, in which participants were required to count carbohydrates and use a 
standard bolus calculator for premeal boluses as per usual practice. Bolus 
calculations as provided by the study pump’s built-in bolus calculator took into 
account carbohydrate content of meals, insulin on board, and entered capillary blood 
glucose readings. The control algorithm was initialized using preprogrammed basal 
insulin delivery downloaded from the study pump. Additionally, information about 
participant's weight and total daily insulin dose were entered at setup. During closed-
loop operation, the algorithm adapted itself to the particular participant. The apparent 
total daily dose was modified based on sensor glucose levels achieved during 
closed-loop on previous days. In the current version of the algorithm this learning 
capability was made more responsive and enhanced adaptability was further 
supported by adaptation to varied insulin needs during the daytime and overnight 
periods. The treat-to-target control algorithm aimed to achieve glucose levels 
between 5.8mmol/l and 7.3mmol/l and adjusted the actual target glucose level 
depending on fasting versus postprandial status and the accuracy of model-based 
glucose predictions. 
Safety precautions during closed-loop 
Participants were trained to perform a calibration check before breakfast and 
evening meal. If the sensor glucose was above the fingerstick glucose by 
>3.0mmol/l, the continuous glucose monitoring device was recalibrated. These 
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instructions resulted from an in silico evaluation of hypoglycemia and hyperglycemia 
risk (24)  using the validated Cambridge simulator (25). 
If sensor glucose became unavailable or in case of other failures, pre-
programmed insulin delivery automatically restarted within 30-60 min. This limited 
the risk of insulin under- and over delivery (36). Safety rules limited maximum insulin 
infusion and suspended insulin delivery if glucose was ≤4.3mmol/l or when sensor 
glucose was rapidly decreasing.  
Assays 
C-peptide measurements were performed using chemiluminescence 
immunoassay (IV2-004; Invitron, Monmouth, UK; inter-assay variation 7.8%, 4.3% 
and 6.7% at 268pmol/l, 990pmol/l and 1,862pmol/l, respectively). Analytical 
sensitivity for the C-peptide assay was 5pmol/l. HbA1c was measured centrally using 
ion exchange high performance liquid chromatography (G8 HPLC Analyzer, Tosoh 
Bioscience, CA, USA; interassay CVs 1.3% at 31.2mmol/mol, 0.8% at 
80.5mmol/mol). 
Questionnaire 
The evaluation of participant-reported outcomes included a trial experience 
questionnaire completed by participants at the conclusion of the closed-loop phase.  
The questionnaire was composed of seven questions, four of which were closed 
questions. The three open questions requested comments and suggestions from 
participants regarding (1) what they liked about the closed-loop system, (2) what 
they did not like about the system, and (3) what additional features they would like to 
have in a closed-loop system.  
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Study outcomes 
The primary efficacy outcome was the proportion of time when glucose was in 
the target range (3.9-10.0mmol/l) during the 21-day study periods as recorded by 
continuous glucose monitoring. Secondary outcomes included mean sensor glucose 
concentrations, glucose variability, time spent at glucose levels <3.9mmol/l 
(hypoglycemia) and >10.0mmol/l (hyperglycemia), and insulin delivery. Secondary 
outcomes were calculated over 24h, daytime and overnight periods; daytime was 
classified between 08:00 and midnight, and night-time between midnight and 08:00. 
Glucose variability was assessed by the standard deviation and the coefficient of 
variation of sensor glucose. Hypoglycemia burden was assessed by calculating the 
glucose sensor area under the curve less than 3.5mmol/l.  
Statistical analysis 
The statistical analysis plan was agreed upon by investigators in advance. All 
analyses were carried out on an intention-to-treat basis. Efficacy and safety data 
from all randomized participants were included in the analyses. The respective 
values obtained during the 21-day randomized interventions were compared using a 
least-square regression model. Sensor glucose and insulin outcomes were adjusted 
for period effect. Rank normal transformation analyses were used for highly skewed 
endpoints. Outcomes were presented as mean ± SD for normally distributed values 
or as median (interquartile range) for non-normally distributed values. Outcomes 
were calculated using GStat software (University of Cambridge, version 2.2). 
Analysis was done using SPSS (IBM Software, Hampshire, UK version 21). A 5% 
significance level was used to declare statistical significance. All p-values are two-
sided. 
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Results 
Participants 
We approached 17 subjects, of whom 12 gave consent/assent and completed 
the study (7 males; age 14.6±3.1 years; diabetes duration 7.8±3.5 years; HbA1c 
8.5±0.7% [69±8mmol/mol]; insulin pump therapy duration 5.5±2.6years; total daily 
insulin dose 0.82±0.18 U/kg/day], all C-peptide negative except for two participants 
with levels of 61 and 262 pmol/l) (Supplemental Material Table S1 and Figure S3). 
Day-and-night glucose control and insulin delivery 
Primary and secondary endpoints are summarized in Table 1. Twenty-four 
hour sensor glucose and insulin delivery profiles are shown in Figure 1. The 
proportion of time that sensor glucose was in the target glucose range 3.9 to 
10.0mmol/l (primary endpoint), was increased during closed-loop compared to 
control period (p<0.001, Table 1). The mean glucose level was significantly lower 
with closed-loop use (p=0.001, Figure 2) as was the time spent above the target 
glucose range (p<0.001). The proportion of time spent with sensor readings in 
hypoglycemia (below 3.9mmol/l and 2.8mmol/l, Figure 2) and the area under the 
curve when sensor glucose was less than 3.5mmol/l were low and comparable 
during the study interventions.  
Glucose variability, measured as the standard deviation and the coefficient of 
variation of sensor glucose level within 24 hours and between days, did not differ 
between study periods. Higher percentage of time when glucose was in target range 
and lower mean glucose levels were achieved by closed-loop through increased 
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variability of basal insulin delivery (p<0.001; Figure 1) and slightly higher total daily 
insulin dose (p=0.006). Basal insulin delivery during closed-loop was significantly 
higher than during control intervention (p=0.001). Overall bolus insulin requirements 
during closed-loop were significantly lower (p=0.009), as was the number of overall 
bolus administrations per day (p=0.015). Fewer correction boluses [0.2 (0.1 to 0.4) 
vs. 0.9 (0.1 to 1.4) per day, closed-loop vs. control, p=0.015] but not meal boluses 
[4.8 (4.6 to 6.1) vs. 5.8 (4.1 to 7.0), p=0.48) were observed during closed-loop. 
Daytime and overnight glucose control and insulin delivery  
Secondary outcomes calculated for daytime (08:00 to midnight) and overnight 
periods (midnight to 08:00) are shown in Table 2. The daytime (p=0.002) and 
overnight (p=0.002) mean glucose were significantly lower during closed-loop use 
(p=0.002). The proportion of time that the glucose level was within the wide target 
range (3.9 to 10.0mmol/l) and overnight target range (3.9 to 8.0mmol/l) were higher 
during closed-loop compared to control (p<0.001) without a difference in total 
daytime and overnight insulin amount. The percentage of time spent with sensor 
readings below target range did not differ between the two interventions during 
daytime and overnight.  
Adverse events 
No serious adverse events or severe hypoglycemic episodes were observed 
during either study period. Three adverse events were documented, none of which 
was related to study devices or study procedures. One participants during control 
intervention measured elevated urine ketone levels associated with hyperglycemia. 
This event was attributed to a viral infection and was self-managed. One participant 
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during closed-loop and another participant during control period required oral 
antibiotic treatment due to respiratory tract infections without metabolic deterioration.  
Utility analysis 
Availability of sensor glucose data was 95% (91% to 98%) during closed-loop 
and higher than 90% (73% to 96%) recorded during control period (p=0.036). 
Closed-loop was operational over 82% (76% to 88%) of time. Overall frequency of 
recorded helpline contacts (device replacement, adverse event reporting) was higher 
during closed-loop: The study pump had to be replaced on three occasions (once 
during run-in, and twice during control period), two translator modules were replaced 
during the closed-loop period, and the closed-loop system had to be reset by 
research staff on eight occasions. 
 
Questionnaire 
All 12 participants completed the questionnaire. Results of the four closed 
questions are shown in Figure S4 (Online Supplement); 100% (12/12) of the 
participants were confident with the closed-loop system regulating their blood 
glucose and insulin delivery. 83.3% (10/ 12) of subjects stated that using the closed-
loop system, they spent less time to manage their diabetes, and two participants 
(16.7%) were unsure about this statement. The majority of participants (91.7% 
[11/12]) expressed fewer concerns about their glucose control while using closed-
loop. Improved sleep was indicated by 75% (9/12) of participants, whereas 8.3% 
(1/12) slept worse, and 16.7% (2/12) were unsure about the impact of the closed-
loop system on their sleep. 
Key positive themes of the closed-loop system as described by participants in 
the free-text section of the questionnaire were improved glucose control, a relief of 
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diabetes management, and specific features of the closed-loop handset allowing 
remote meal bolusing and data review. Key negative themes were the number and 
size of devices, the necessity to carry around the equipment all the time, CGM and 
pump alarms, connectivity and CGM calibration issues. According to participants, 
future closed-loop systems should be smaller, ideally integrating all different devices 
into one single device. Sensor life should be longer, and additional features to 
facilitate carbohydrate estimation should be implemented. 
 
Conclusions 
To our knowledge, this is the longest randomized controlled trial investigating 
day-and-night application of closed-loop insulin delivery in adolescents with type 1 
diabetes during free-living conditions. We demonstrate the feasibility and benefits of 
prolonged use of single hormone 24/7 closed-loop. It increased the time when 
glucose was in the target range by 19 percentage points whilst reducing mean 
glucose by 1.8mmol/l. Though more insulin was delivered during closed-loop in 
these suboptimally controlled adolescents, improvements were achieved without 
increasing the risk of hypoglycemia.  
The present study extends findings from our previous home trials in children 
and adolescents (19; 21; 22), which were limited by either overnight application (19; 
21) or a shorter intervention period (22). While benefits of closed-loop in these trials 
as well as in our previous adult trials (21; 26) tended to be greater overnight 
compared to daytime, results of the present study show consistent improvements in 
glucose levels overnight and during daytime. Possible explanations include closed-
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loop mitigating against missed meal boluses in suboptimally controlled adolescents. 
Additionally, we applied control algorithm with enhanced adaptivity. Poorly controlled 
teenagers may be among those most benefiting from closed-loop systems. 
Hypoglycemia rates were low, and there was no significant difference in the 
time spent in hypoglycemia between interventions in line with findings from our 
previously published 24/7 closed-loop home trial in adolescents (22). Significant 
reductions in hypoglycemia risk were observed in populations with greater rates of 
hypoglycemia or in more challenging environments such as diabetes camps during 
prolonged outpatient closed-loop studies in adults using single-hormone (21; 27) or 
dual hormone (glucagon co-administration) closed-loop approaches across different 
age groups (16-18). 
Prolonged periods of sensor under-reading resulting in hypoglycemia over-
reporting were identified in one participant during closed-loop intervention 
underscoring challenges associated with quantifying hypoglycemia using glucose 
sensor data. No similar findings were observed during control intervention. While 
results in Table 1 & 2 and in the results section are based on the original data, 
Figure 2 shows data excluding periods of sensor under-reading (see Figure S5 to 
S9, Supplemental Material, for details of excluded data).  
Total daily insulin requirements during closed-loop were modestly higher than 
during control intervention, which was due to higher basal insulin delivery. Inherent 
to closed-loop systems, algorithm directed insulin delivery was more variable than 
basal insulin delivery during the control period. More pronounced increases in total 
insulin delivery during closed-loop intervention [24% (28) to 33% (16) of total daily 
insulin dose] were previously described in studies of dual hormone systems, where 
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potential insulin overdosing can be mitigated by co-administration of glucagon. 
Higher insulin requirements during closed-loop in the present study may reflect 
underinsulinisation in sub-optimally controlled adolescents. Of interest, we observed 
reduced bolus amounts and fewer boluses per day during closed-loop intervention. 
We attribute this finding to fewer correction doses, but the observation could also 
reflect reduced bolus adherence for meals and snacks during closed-loop. The 
unsupervised design of the study precludes reliable interpretation of the finding.  
Closed-loop usage and sensor wear were high. The closed-loop technology 
was well perceived in line with previously published data (29). Though the number of 
devices and system alarms were reported to be drawbacks, participants expressed 
trust in the technology, and reduced burden of diabetes including a less time spent to 
manage diabetes and fewer worries about glycemic control. Further miniaturization 
and integration of devices, prolonged sensor life, and simplified meal management 
are preferable features of future closed-loop systems which may enhance usability. 
A fully closed-loop system without meal announcement would be particularly 
applicable in the adolescent population. However, the absorption rate of currently 
available rapid acting insulin analogues is not fast enough to effectively control 
postprandial glucose excursions without anticipatory insulin bolus. Our premise is 
that present closed-loop systems will benefit from meal announcement but have to 
be able to cope with missed meal boluses safely and efficaciously, should these 
occur.  
The strengths of our study include randomized crossover design, the 
integration of closed-loop into normal life with participants performing their usual 
free-living activities while at home or at school, and during weekends and holidays. 
The study was performed without remote monitoring or close supervision to assess 
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real-world applicability of the technology. We did not restrict participants’ dietary 
intake, physical activity or geographical movement. The comparator was state-of-
the-art sensor-augmented insulin pump therapy. Weaknesses include a small 
sample size and the need to carry multiple devices during closed-loop intervention.  
The study duration was still relatively short. 
In conclusion, we found that use of a day-and-night hybrid closed-loop system 
at home over a period of 21 days during free daily living without close supervision is 
feasible, safe and effective in suboptimally controlled adolescents with type 1 
diabetes. Benefits include increased time when glucose is in the target range and 
reduced mean glucose. Larger and longer studies are warranted. 
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TABLES 
Table 1.  Comparison of glucose control and insulin delivery during closed-loop and 
control period over 21 days. 
 Closed-loop 
(n=12) 
Control 
(n=12) 
Paired  
difference* 
p 
 
Day-and-night glucose control 
    
Time spent at glucose level (%)     
 3.9 to 10.0mmol/l† 66.6±7.9 47.7±14.4 18.8±9.8 <0.001 
 >10.0mmol/l 29.7±9.2 49.1±16.5 -19.3±11.3 <0.001 
 >16.7mmol/l 5.1 (0.8 to 5.6) 8.0 (1.9 to 17.4) -3.6 (-11.9 to -0.65) <0.001 
 <3.9mmol/l 4.3 (1.4 to 5.2) 2.4 (0.3 to 5.7) 0.4 (-2.2 to 1.3) 0.33 
 <2.8mmol/l 0.3 (0.0 to 0.5) 0.1 (0.0 to 0.7) -0.1 (-0.4 to 0.2) 0.49 
AUCday <3.5mmol/l (mmol/l x min)
 ‡ 11.1 (1.2 to 17.4) 2.7 (0.2 to 20.4) 0.0 (-10.5 to 6.8) 0.21 
Mean glucose (mmol/l) 8.7±0.9 10.5±1.8 -1.8±1.3 0.001 
Within day SD of glucose (mmol/l) 3.7±0.7 4.2±0.8 -0.5±0.7 0.013 
CV of glucose within day (%) 40.5 (38.1 to 47.7) 38.3 (36.7 to 43.7) 1.2 (-2.6 to 6.7) 0.18 
CV of glucose between days (%) 19.0 (13.8 to 23.7) 17.4 (14.9 to 24.0) -0.5 (-3.9 to 6.0) 0.94 
Day-and-night insulin delivery     
Total daily insulin (U/day)
 53.5 (39.5 to 72.1) 51.5 (37.6 to 64.3) 4.5 (1.6 to 6.5) 0.006 
Total bolus insulin (U/day) 28.3 (16.7 to 32.6) 29.4 (23.6 to 37.6) -4.4 (-8.1 to -1.4) 0.009 
Total basal insulin (U/day) 25.8 (23.0 to 41.2) 19.9 (14.8 to 26.3) 7.6 (3.8 to 14.4) 0.001 
SD of basal insulin delivery (U/hour) 1.2 (1.0 to 1.9) 0.3 (0.1 to 0.3) 1.1 (0.8 to 1.6) <0.001 
CV of basal insulin delivery 106.7 (97.2 to 111.1) 23.9 (12.8 to 35.2) 79.2 (77.1 to 91.3) <0.001 
Bolus administrations (Number/day) 4.9 (4.8 to 6.3) 6.3 (5.1 to 7.6) -1.1 (-1.5 to -0.2) 0.015 
Data are presented as mean±SD or median (interquartile range). p-values adjusted for period effect. 
*Closed-loop minus control. A positive value indicates the value was higher on the closed-loop compared with 
control 
† Primary endpoint 
‡AUCday, Glucose area under curve below 3.5mmol/l per day 
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Table 2. Daytime and night-time glucose control and insulin delivery during closed-
loop and control period. 
 Closed-loop 
(n=12) 
Control 
(n=12) 
Paired  
difference* 
p 
Daytime 
(from 08:01 to 23:59) 
  
 
 
Time spent at glucose level (%)     
 3.9 to 10.0mmol/l 62.9±8.9 45.7±13.7 17.1±12.2 0.001 
 >10.0mmol/l 33.0±10.7 51.8±15.7 -18.7±13.7 0.001 
 <3.9mmol/l 4.2 (1.0 to 6.5) 1.2 (0.3 to 3.9)  0.3 (-0.8 to 4.1) 0.15 
AUCday <3.5mmol/l (mmol/l x min) † 11.2 (0.9 to 17.0) 2.0 (0.2 to 12.3) -0.4 (-5.0 to 12.8) 0.26 
Mean glucose (mmol/l) 9.0±1.0 10.8±1.9 -1.8±1.5 0.002 
Within day SD of glucose (mmol/l) 3.9±0.8 4.3±0.9 -0.4±0.9 0.10 
CV of glucose within day (%) 42.8 (37.9 to 49.8) 39.0 (36.0 to 42.6) 3.0 (-3.7 to 8.7) 0.20 
CV of glucose between days (%) 19.2 (17.4 to 25.6) 21.6 (16.5 to 23.1) -2.4 (-5.8 to 3.5) 0.86 
Daytime insulin delivery (U) 42.7 (31.2 to 53.6) 42.8 (30.9 to 48.4) 3.5 (0.0 to 6.3) 0.24 
Night-time 
(from midnight to 08:00) 
    
Time spent at glucose level (%)     
 3.9 to 8.0mmol/l 54.4±13.8 33.4±16.3 20.9±12.7 <0.001 
 >8.0mmol/l 42.8±14.0 62.0±19.4 -19.3±14.5 0.001 
 <3.9mmol/l 2.5 (1.1 to 4.2) 3.9 (0.3 to 7.2) -1.3 (-4.9 to 1.4) 0.70 
AUCday <3.5mmol/l (mmol/l x min)*
 
 5.3 (1.6 to 19.7) 4.7 (0.0 to 21.8) 1.2 (-20.0 to 5.9) 0.56 
Mean glucose (mmol/l) 8.2±1.1 9.8±2.0 -1.6±1.4 0.002 
Within night SD of glucose (mmol/l) 3.1±0.9 3.8±0.7 -0.7±0.7 0.008 
CV of glucose within night (%) 37.3±6.8 39.3±7.3 -2.0±9.9 0.53 
CV of glucose between nights (%) 26.7±8.5 
30.9±6.4 -4.2±10.1) 0.20 
Overnight insulin delivery (U) 11.5 (9.5 to 17.3) 11.0 (8.5 to 15.0) 0.6 (-0.5 to 3.5) 0.18 
Data are presented as mean±SD, median (interquartile range) 
* Closed-loop minus control. A positive value indicates the value was higher on the closed-loop compared with control 
†AUCday, glucose area under curve below 3.5mmol/l per day  
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FIGURE LEGENDS 
Figure 1.  Median (interquartile range) of sensor glucose (top panel) and insulin 
delivery (bottom panel) during closed-loop (solid red line and red shaded area) and 
control period (dashed black line and gray shaded area) from midnight to midnight. 
The glucose range 3.9 to 10.0 mmol/l is denoted by horizontal dashed lines (top 
panel). 
 
Figure 2.  Individual values of mean sensor glucose during day-and-night closed-loop 
study. The size of bubble indicates the proportion of time spent with low glucose 
below 2.8mmol/l. 
 
 
